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Diagnosis of cytomegalovirus pneumonitis following stem cell 
transplantation: addressing the Yin and Yang of molecular methods. 
 
In the early days of allogeneic stem cell transplantation, pneumonitis caused 
by cytomegalovirus (CMV) was a feared complication with a high mortality 
whose diagnosis could only be made by lung biopsy.(1) The occurrence of 
disease once the marrow had engrafted, coupled with interstitial infiltration of 
the lungs with lymphocytes, suggested the possibility of an 
immunopathological component to the pathogenesis, triggered by the 
presence of CMV.(2) Simply detecting CMV infection in the lungs may not 
diagnose current CMV pneumonitis with high specificity, yet may be a 
harbinger for its future development in some patients.(3) 
 
Once ganciclovir became available, investigators sought evidence of active 
CMV infection in the lungs by using bronchoalveolar lavage and processing 
the samples with the then new technology of cell culture confirmation based 
on monoclonal antibodies specific for CMV.(4, 5) In a pioneering study in 
1991, researchers sampled the lungs on day 35 post-transplant in 104 
patients and again later in some of them.(6) When CMV was detected at day 
35, patients were offered randomization to standard care or to receive 
intravenous ganciclovir in addition. Receipt of this drug significantly reduced 
the primary endpoint of death or CMV pneumonitis from 70% (14/20) to 25% 
(5/20). In an accompanying editorial, Dr Bob Rubin coined the term pre-
emptive therapy to describe the strategy of detecting CMV infection early post 
transplant and treating it before it evolved into serious disease.(7) His 
inspiration for this terminology came from watching live television broadcasts 
showing cruise missiles destroying ground radar systems so that death from 
subsequent manned conflict could be reduced during the First Gulf War. Thus, 
that war and the term pre-emptive therapy both celebrated their 25th 
anniversaries last year.(8) While the clinical trial took a major step forward, it 
was not sufficient to control all cases of CMV disease, because the study also 
reported that repeated sampling for CMV infection would be required to 
identify all patients destined to develop CMV pneumonitis.(6) There were 
obvious practical difficulties to performing serial BALs but, fortunately, the 
description of polymerase chain reaction (PCR) allowed CMV DNA to be 
detected in blood.(9) Monitoring stem cell transplant patients serially for 
DNAemia thus replaced routine day 35 bronchoalveolar lavage, although the 
term, pre-emptive therapy, was retained. 
 
In those days, PCR for CMV DNA was qualitative. Research assays showed a 
link between the quantity of CMV in the blood (CMV viral load) and CMV end-
organ disease, but were not applicable to routine clinical diagnosis.(10) 
Around 2003, real-time PCR became available and was quickly taken up by 
many laboratories to diagnose CMV DNAemia. Just as PCR became useful 
for testing blood, it was also widely adopted for other samples including 
BAL.(11) This meant that the classical techniques of traditional cell culture 
with cytopathic effect as a readout, or monoclonal antibodies for cell culture 
confirmation, were less likely to be requested. With time, these older assays 
disappeared from the repertoire of diagnostic laboratories. There was clear 
patient benefit from the availability of rapid molecular diagnosis because this 
undoubtedly was one factor that contributed to the decreasing incidence of 
CMV pneumonitis (reviewed in (1)). 
 
The Yang that corresponds to this Ying is the absence of data to document 
the sensitivity and specificity of PCR when different viral loads are detected in 
BAL. This is a concern, because these immunocompromized hosts do not 
suffer from individual opportunistic infections one at a time; multiple infections 
may be present, only some of which contribute to pathogenesis. Available 
treatments also have important side effects, such as the bone marrow toxicity 
of ganciclovir, so accurate diagnosis is required to guide therapy in these 
complex patients who are already receiving multiple drugs. Furthermore, 
definitive diagnostic criteria are required as strict endpoints for clinical trials of 
newer antiviral drugs and vaccines with potential activity against CMV.(12) 
 
How could clinical researchers address this problem? No one would advocate 
returning to definitive diagnosis through invasive lung biopsy in this group of 
vulnerable patients. Case series and collective clinical experience of BAL 
coupled with clinical diagnoses can accumulate and be shared, but can only 
provide the weakest type of scientific evidence. Current clinical guidelines that 
recognize the need for robust diagnosis for confirmed cases of CMV 
pneumonitis, state(12) that "detection of CMV by PCR alone may be too 
sensitive for the diagnosis of CMV pneumonia." This statement is prescient, 
for this issue of the journal contains much-needed quantitative data.(13) 
 
Researchers at Fred Hutchinson Cancer Centre in Seattle reviewed their case 
series of CMV pneumonitis in 132 patients post stem cell transplant. The 
quantitative PCR results from the clinically diagnosed cases of CMV had a 
median log10 of 3.9 (IQR 2.6-6.0) IU/ml BAL fluid. A control group was 
provided by 118 stem cell transplant patients whose pneumonia was 
attributed to infectious agents other than CMV. The quantitative PCR results 
from these patients with non-CMV pneumonia showed a median log10 viral 
load of 0 (IQR 0-1.6) IU/ml. Importantly, the researchers provide another 
control group; patients who volunteered in 1988-89 to be part of a natural 
history study by undergoing BAL at day 35-45 post stem cell transplant.(3) 
The median log10 viral load in these controls was 1.6 (IQR 0-2.5) IU/ml. Both 
groups of control patients were at risk of CMV infection by virtue of recipient 
or donor seropositivity pre-transplant. Thus, CMV DNA can be detected at low 
levels in BAL of some stem cell patients with pneumonia attributed to other 
infections or in those without overt disease. However, the levels so low that 
they can be distinguished from the higher levels found in cases of true CMV 
pneumonitis.(13)  
 
To critically assess the diagnostic value of these quantitative results, the 
authors constructed receiver operator curves from the values in BAL samples 
obtained before treatment was started. The positive predictive values and 
negative predictive values are given for particular levels of CMV DNA found in 
BAL, with a suggested optimum cut-off of 500 IU/ml. The results are analyzed 
and presented in multiple ways to allow individual transplant centers to set 
their diagnostic cut-off values to suit the baseline characteristics of their 
patients and expected prevalence of CMV pneumonitis. In addition, they show 
that the results are not affected by the presence of co-pathogens or 
pulmonary hemorrhage. Portability of the results between centers is facilitated 
by expressing the PCR values in international units/ml of BAL fluid.(14) The 
results also bring to mind a new design for a randomized controlled trial. Once 
the value of 50 IU/ml is accepted as the cut-off to initiate therapy with 
ganciclovir and immunoglobulin, patients with lower levels could be 
randomized to receive an anti-CMV drug or placebo to see if future 
pneumonitis could be prevented. At the moment, such a study would have the 
disadvantage of giving a drug that is toxic to bone marrow, but the availability 
of one of three new compounds that lack such side-effects would change the 
risk-benefit calculation.(15-17) 
 
Overall, this paper is a tour de force that illustrates the importance of 
incorporating natural history studies into translational research projects. The 
heroes of this paper are arguably the patients who selflessly volunteered to 
have BAL performed 35-45 days after their stem cell transplant. The results in 
these altruists have elevated this report from a standard well-controlled case 
series to a seminal publication that will be widely used and cited, thus 
illustrating the benefits for both science and medicine of clinically-relevant 
academic health research. 
 
PD Griffiths 
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